Cost & coverage Q&A — answered honestly
Real questions people ask about affording a GLP-1 — denials, prior auth, savings, Medicare, Medicaid — answered only where our sourced facts support an answer, and human-reviewed before publishing. We help with cost and coverage; medical decisions belong to your clinician.
Why Is the Discussion Focused on Cost for GLP-1 Medications?
Exploring the reasons behind the emphasis on cost in discussions about GLP-1 medications.
VERIFIED FROM SOURCESTips for Appealing an Insurance Exclusion for a Medically Necessary Procedure
Learn effective strategies for appealing an insurance denial for medically necessary procedures.
VERIFIED FROM SOURCESHow to Address Prior Authorization Issues with Ozempic
Steps to navigate prior authorization challenges for Ozempic when your primary care provider is unable to assist.
VERIFIED FROM SOURCESWhat is Commercial Insurance in the Context of GLP-1 Medications?
Understanding what constitutes commercial insurance can help you navigate coverage for GLP-1 medications.
VERIFIED FROM SOURCESFrequently asked questions
No U.S. law forces every plan to cover a GLP-1 for weight loss, so whether yours does comes down to your specific plan — and, for Medicaid, your state. Coverage for a GLP-1 prescribed for type 2 diabetes is far more common than coverage for weight loss. Check the Medicaid-by-state map or the Medicare GLP-1 Bridge, and if you are turned down you usually have the right to appeal the denial.
It is the difference that most often decides whether a plan pays. The FDA approves each drug for a specific use: Ozempic and Mounjaro are approved to treat type 2 diabetes, while Wegovy and Zepbound are approved for chronic weight management in adults who meet weight criteria. Compare them on our drugs page. Source: U.S. FDA ↗ (as of June 2026).
Be careful. The FDA has warned that compounded and counterfeit GLP-1 products can contain the wrong dose or the wrong ingredients, and it has logged more than a thousand adverse-event reports tied to compounded semaglutide and tirzepatide. As the official shortages resolved, the legal basis for mass compounding is being phased out — see the safe, legitimate alternatives on our compounding and cost pages. Source: U.S. FDA ↗.
Often, yes. Insurers deny on specific, listed criteria, and a documented appeal that maps your record to those criteria overturns a meaningful share of denials. Our appeal guide has the exact steps plus a letter-of-medical-necessity template to take to your prescriber.
We publish an answer only where our dated, sourced facts support one, and a human reviews each one before it goes live. Questions we cannot yet confirm are listed openly on our Open Questions page instead of guessed — see our methodology for the full standard.